Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma.
Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma.
复制标题
DOI：
10.6004/jadpro.2019.10.8.9
复制
发表时间：
2019-11-01
期刊：
影响因子：
--
通讯作者：
Orozco, Jennifer S
中科院分区：
文献类型：
--
作者：
King, Amber C;Orozco, Jennifer S
Axicabtagene ciloleucel (axi-cel) 是一种抗 CD19 CAR T 细胞疗法，已证明对传统疗法反应不佳的复发性难治性弥漫性大 B 细胞淋巴瘤 (DLBCL) 患者有效。赋予 axi-cel 功效的免疫激活是以潜在的破坏性不良现象为代价的：细胞因子释放综合征和神经毒性。本文对 axi-cel 进行了概述，包括对现有临床证据、作用机制以及 axi-cel 一些独特毒性的管理的回顾。
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy in relapsed and refractory diffuse large B-cell lymphoma (DLBCL) patients who have had suboptimal responses to conventional therapies. The immune activation that confers the efficacy of axi-cel comes at the price of potentially devastating adverse phenomena: cytokine release syndrome and neurotoxicity. This article serves as an overview of axi-cel, including a review of the available clinical evidence, mechanism of action, and management of some of the unique toxicities of axi-cel.